|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.20 USD | -0.08% |
|
+0.03% | -4.95% |
| 10/04 | Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says | MT |
| 10/04 | BofA Adjusts Price Target on Ionis Pharmaceuticals to $111 From $100, Maintains Buy Rating | MT |
| Capitalization | 12.43B 10.56B 9.75B 9.19B 17.05B 1,157B 17.34B 114B 44.78B 557B 46.64B 45.67B 1,979B | P/E ratio 2026 * |
-18.4x | P/E ratio 2027 * | -67.3x |
|---|---|---|---|---|---|
| Enterprise value | 12.05B 10.23B 9.45B 8.91B 16.53B 1,121B 16.81B 111B 43.41B 539B 45.21B 44.27B 1,918B | EV / Sales 2026 * |
14.6x | EV / Sales 2027 * | 8.43x |
| Free-Float |
99.23% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Ionis Pharmaceuticals, Inc.
| 1 day | -0.08% | ||
| 1 week | +0.03% | ||
| Current month | +0.14% | ||
| 1 month | +3.96% | ||
| 3 months | -3.01% | ||
| 6 months | +2.88% | ||
| Current year | -4.95% |
| 1 week | 73.9 |  | 77.38 |
| 1 month | 68.9 | | 77.38 |
| Current year | 68.9 | | 86.74 |
| 1 year | 27.9 | | 86.74 |
| 3 years | 23.95 | | 86.74 |
| 5 years | 23.95 | | 86.74 |
| 10 years | 19.59 | | 86.74 |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
B. Parshall
BRD | Director/Board Member | 71 | 01/09/2000 |
Joseph Wender
BRD | Director/Board Member | 81 | 01/01/1994 |
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.08% | +0.03% | +164.77% | +99.03% | 12.43B | |
| +2.22% | +5.51% | +0.78% | -7.93% | 47.35B | |
| +1.65% | +5.36% | +41.25% | +23.21% | 35.57B | |
| +0.39% | +55.82% | +308.76% | +511.56% | 31.16B | |
| +3.56% | +6.46% | +23.79% | -12.08% | 28.86B | |
| -0.72% | +2.98% | +35.64% | +28.89% | 29.62B | |
| +0.23% | +1.60% | +47.29% | +193.75% | 15.01B | |
| +1.20% | +4.97% | +74.85% | +164.95% | 14.73B | |
| -4.97% | +0.62% | +3,684.42% | +3,881.33% | 15.12B | |
| +0.87% | +8.85% | +40.89% | +13.56% | 14.34B | |
| Average | +0.31% | +9.05% | +442.24% | +489.63% | 24.42B | |
| Weighted average by Cap. | +0.63% | +10.62% | +298.99% | +337.17% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 827M 703M 649M 612M 1.13B 76.99B 1.15B 7.6B 2.98B 37.04B 3.1B 3.04B 132B | 1.41B 1.2B 1.11B 1.04B 1.94B 131B 1.97B 12.97B 5.08B 63.2B 5.3B 5.19B 225B |
| Net income | -665M -564M -521M -491M -911M -61.85B -927M -6.11B -2.39B -29.76B -2.49B -2.44B -106B | -211M -179M -165M -156M -289M -19.6B -294M -1.94B -759M -9.43B -790M -774M -33.52B |
| Net Debt | -381M -323M -299M -282M -522M -35.44B -531M -3.5B -1.37B -17.05B -1.43B -1.4B -60.63B | -530M -450M -415M -392M -726M -49.29B -739M -4.87B -1.91B -23.71B -1.99B -1.95B -84.32B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/04/26 | 75.14 $ | -0.17% | 393,185 |
| 16/04/26 | 75.26 $ | -2.03% | 1,873,899 |
| 15/04/26 | 76.82 $ | +0.08% | 1,288,372 |
| 14/04/26 | 76.76 $ | +2.41% | 1,595,277 |
| 13/04/26 | 74.95 $ | -0.29% | 1,650,871 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IONS Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition